Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective in patients with EGFR-TKI sensitizing and T790M resistant mutationpositive advanced non-small cell lung cancer (NSCLC) [1, 2] . Although interstitial lung disease (ILD) is a serious adverse drug reaction of EGFR-TKIs [3] , the prevalence of and risk factors for ILD following the practical use of osimertinib remain unknown. Here we report the incidence of ILD related to osimertinib use at the Shizuoka Cancer Center.
Following ethical approval in Japan, we administered osimertinib to 19 Japanese patients with EGFR-T790M mutation-positive advanced NSCLC and disease progression on or after EGFR-TKI therapy between 28 March and 30 June 2016. All 19 patients were diagnosed with advanced lung adenocarcinoma and were administered 80 mg osimertinib once daily. Of these patients, four (21%) developed ILD (two patients with grade 1, one patient with grade 2, and one patient with grade 3). Clinical identification of ILD was based on the assessment of computed tomographic imaging (Supplementary figure S1, available at Annals of Oncology online) and pathologic features of lung biopsy specimen [4] . The median time to the onset of ILD from osimertinib initiation was 6 (range, 4-12) weeks. Osimertinib was discontinued in all four patients, and systemic steroids were started in two patients, which resulted in events either resolving or being resolved. The baseline characteristics of patients with and without ILD are presented in Table 1 . The frequency of immediate prior treatment with nivolumab, an anti-programmed death-1 (PD-1) immune checkpoint-inhibitor, was higher (75 versus 13%, P ¼ 0.04, Fisher's exact test) and the interval between the final administration of prior nivolumab and the initiation of osimertinib tended to be shorter (median, 2 versus 7 weeks, P ¼ 0Á08, Wilcoxon rank-sum test) in patients with ILD than in those without ILD.
Previous clinical trials reported an incidence of osimertinibinduced ILD in Japanese patients of 6.3% (5/80), which differed from the practical use of osimertinib in our institution, particularly in patients who underwent immediate prior nivolumab therapy. Recently, Ahn et al. [5] reported the results of a combination of osimertinib and durvalumab, an anti-PDligand 1 (PD-L1) immune checkpoint-inhibitor, for the treatment of EGFR mutation-positive NSCLC. The study included 34 patients who received concurrent administration of osimertinib (80 mg once daily) and durvalumab (3 or 10 mg/kg every 2 weeks). ILD was observed in 38% (13/34) of all patients and 60% (6/10) of Japanese patients; it was also observed in 60% (3/5) of Japanese patients who underwent immediate prior nivolumab therapy at our institution. Both nivolumab and durvalumab are monoclonal antibodies that block the PD-1/PD-L1 negative regulatory pathway in antitumor immune responses and restore T-cell antitumor function. Enhancement of T-cell effector function by anti-PD-1/PD-L1 immune checkpoint inhibitors may have the harmful effect of increasing osimertinib-induced ILD risk.
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Integrating communication as a core skill in the global curriculum for medical oncology
A recent editorial paid attention to the third edition (2016) of the joint European Society for Medical Oncology and American Society of Clinical Oncology (ESMO/ASCO) recommendations for a global curriculum in medical Oncology (GC) [1] . The new version answers to the need for updated recommendations in a continuously changing field of oncology where a broad range of competences need to be acquired for delivering qualitative and comprehensive oncological care. Future medical oncologists, who are at the centre of cancer care, need to be supported in developing adequate competences. Moreover, recommendations are of utmost importance to pursue equal chances of receiving state-of-the-art treatment from welltrained physicians for every patient worldwide.
A comparative content analysis of the first, second and third edition of the recommendations reveals that mainly clinical and treatment aspects of cancer care are the focal point of all three versions. Possessing the knowledge and skills to be able to assess clinical details adequately with sometimes complex co-morbidity is crucial, along with the skills to identify and administer the appropriate anti-cancer therapies. However, cancer trajectories also require interpersonal and communication competences to discuss difficult topics, such as bad news communication, explaining different treatment options and possible clinical trials, obtaining informed consent and discussing transitions from curative-intended therapy to palliative care. It has been demonstrated that communication and interpersonal skills can be taught and learned. They are not just mere personality traits, natural talent or automatically acquired through experience [2] . Growing evidence shows that good communication skills and effective and empathic communication with cancer patients' influences desirable outcomes such as quality of life, satisfaction with care given, and medical outcomes [3] . Moreover, oncologists are Letters to the editor Annals of Oncology
